All articles by
Corium and Lotus Pharmaceutical partner for Alzheimer’s drug Adlarity
Under the partnership, Lotus will oversee obtaining regulatory approval and will have the sole right to market Adlarity in the applicable country and Corium will oversee the supply of finished goods to Lotus
City of Hope researchers develop a CAR T cell therapy for advanced ovarian cancer
Preclinical research published in Nature Communications details safety and effectiveness of the investigational therapy now in a Phase 1 clinical trial
WHO classifies new Covid-19 strain EG.5 as variant of interest
Informally referred to as Eris, the new strain descends from the lineage of XBB.1.9.2, and would pose relatively less public health risk, compared to XBB.1.16 and the other currently circulating VOIs, based on available evidence
Novartis’ remibrutinib met primary endpoints in two Phase III CSU trials
At week 12, both Phase 3 studies’ primary endpoints of absolute change from baseline in the weekly UAS7 were reached, showing statistically significant and clinically meaningful improvements in disease activity
Lilly Completes Acquisition of DICE Therapeutics
The acquisition expands Lilly’s immunology portfolio to include DICE’s novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology
VANFLYTA Now Available in US for Patients with Newly Diagnosed FLT3-ITD Positive AML
VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated
SK bioscience to acquire 7% stake in Novavax to boost partnership
Under the investment, SK bioscience will acquire a 7% stake or 6.5 million shares of Novavax’s common stock for $84.5m in lieu of some of Novavax’s payment owed to the South Korean biotech company
Emergent BioSolutions to strengthen core business and financial position
The company is planning to cut operations at its Canton, Massachusetts, facility and Rockville, Maryland factory and lay off about 400 employees across the organisation
Novo Nordisk’s semaglutide meets primary objective in SELECT trial
The cardiovascular outcomes trial evaluated subcutaneous once-weekly semaglutide 2.4mg against placebo as an adjunct to the standard of care to prevent MACEs over a five year period
NRx Pharmaceuticals licenses US patent to support NRX-101 use in chronic pain
The patent is backed by vast nonclinical data and early clinical data that point to the potential for NMDA antagonist drugs such as NRX-101 to reduce both chronic pain and neuropathic pain while reducing opioid cravings